ICER Releases Draft Guidance Supporting Cost-Effectiveness of $2 Million Sickle Cell Gene Therapy

The Institute of Clinical and Economic Review (ICER) has issued a draft guidance supporting the use of two different gene therapies for sickle cell disease. The treatments, developed by Vertex and CRISPR Therapeutics, both run around $2 million per treatment, but ICER argues that the high price tag could be cost effective in some cases.

According to Zachary Brennan, “ICER noted that the proportion of patients achieving treatment success was estimated at about 97% for both therapies, based on the data from the lovo-cel pivotal trial that suggested 30 out of 31 have no further vaso-occlusive crises (VOCs).”

To read more, click here.

(Source: Endpoints News, April 12^th, 2023)